Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Fig. 4

Pre-treatment circulating B lymphocyte differentiation status associated with patient outcomes. a Baseline (pre-treatment) percentages of indicated B lymphocytes differentiation status (Bm2 and eBm5 + Bm5), according to the Bm classification (sIgD and CD38; see Additional file 1: Figure S4A for nomenclature and gating strategy), according to response status. Each point represents a donor, average is outlined, and error bars represent SEM. ns: not significant; *: p < 0.05; **: p < 0.01, from a one-way ANOVA with Bonferroni post hoc test. b Kaplan-Meier OS curves for the Bm2 and eBm5 + Bm5 populations, stratified by percentages above (high) or below (low) the mean percentage for each population. P values were calculated using the log-rank test and are shown on each graph

Back to article page